Psoriasis is far more than a cosmetic nuisance. It is a chronic immune-mediated condition affecting roughly two to three percent of the global population, characterized by scaly, red, often itchy plaques driven by runaway inflammatory signaling in the skin. Decades of research have established that the disease is not confined to the epidermis: people with psoriasis carry elevated risks of cardiovascular disease, metabolic syndrome, depression, and psoriatic arthritis. Yet diagnosing and tracking the systemic inflammatory burden of psoriasis remains challenging in everyday clinical practice. Physicians typically rely on visual assessment of skin involvement and, when available, inflammatory markers such as C-reactive protein, none of which perfectly capture the whole-body picture. This gap has fueled an intense search for inexpensive, reproducible biomarkers that reflect the interplay between inflammation and nutrition.

Enter RAR, a composite index that combines two routinely measured blood values into a single number. The first component, red cell distribution width, or RDW, quantifies the variation in size among circulating red blood cells. A narrow, uniform population of erythrocytes yields a low RDW, while a heterogeneous mix pushes the value upward. Hematologists have long known that RDW rises in conditions of chronic inflammation, oxidative stress, nutritional deficiency, and disordered erythropoiesis, and elevated RDW has repeatedly been linked to worse outcomes in heart failure, myocardial infarction, sepsis, stroke, and chronic kidney disease. The second component, serum albumin, is the most abundant protein in human plasma, synthesized by the liver and well established as a negative acute-phase reactant: when systemic inflammation flares, albumin synthesis is suppressed and levels fall. Albumin also serves as a broad proxy for nutritional status, liver function, and even the anticoagulant properties of blood plasma.

By dividing RDW by albumin concentration, RAR effectively captures two sides of the inflammatory coin at once: a numerator that climbs as inflammation and oxidative stress perturb red cell maturation, and a denominator that sinks as the same inflammatory cascade dampens hepatic protein synthesis. The ratio has already shown prognostic value in heart failure, atrial fibrillation, rheumatoid arthritis, diabetes-related foot ulcers, and acute ischemic stroke, where higher values tracked with increased mortality. What remained unclear was whether RAR also relates to the prevalence of a chronic inflammatory skin disease in the general population, which is precisely the question the research team, led by dermatologists at The First Affiliated Hospital of Jinan University in Guangzhou, China, set out to answer.

To do so, the investigators turned to the National Health and Nutrition Examination Survey, or NHANES, a long-running program of the National Centers for Health Statistics that combines interviews, physical examinations, and laboratory testing on a sample designed to represent the civilian, non-institutionalized US population. The team pooled six survey cycles spanning 2003 to 2006 and 2009 to 2014, yielding 11,668 adults with complete data on both RDW and serum albumin. Within this cohort, 280 participants reported a clinician-confirmed diagnosis of psoriasis. The researchers calculated RAR for every participant, applied a natural logarithmic transformation to normalize its distribution, and then deployed multivariable logistic regression to ask whether ln-RAR was independently associated with psoriasis prevalence after accounting for a comprehensive set of potential confounders.

The results were striking. In the fully adjusted model, higher ln-RAR was independently associated with roughly 3.57-fold higher odds of psoriasis, with a 95 percent confidence interval of 1.37 to 8.92 and a P value of 0.003. In other words, even after statistical adjustment for demographic, lifestyle, and clinical factors, adults whose blood chemistry reflected greater red cell size variability relative to their albumin levels were markedly more likely to carry a psoriasis diagnosis. Crucially, the association was not confined to a narrow slice of the data. Restricted cubic spline analysis, a flexible modeling technique that allows the relationship between exposure and outcome to take any shape, confirmed a linear dose-response pattern: the risk of psoriasis rose steadily and proportionally across the RAR spectrum, with no evidence of a threshold effect or non-linear inflection.

Robustness checks reinforced the central finding. In subgroup analyses stratified across clinically relevant population segments, the effect size of RAR on psoriasis presence remained stable, with all interaction P values exceeding 0.05, meaning the association did not meaningfully differ by subgroup membership. Sensitivity analyses, which re-ran the models under alternative assumptions and specifications, produced results consistent with the primary analysis. For a cross-sectional study, which by design captures a single moment in time and cannot establish causation, this degree of internal consistency across analytic approaches lends considerable weight to the conclusion that the RAR-psoriasis link is not a statistical artifact.

The biological plausibility of the association is grounded in well-characterized mechanisms. Chronic inflammation in psoriasis is driven by cytokines such as tumor necrosis factor-alpha, interleukin-17, and interleukin-23, which orchestrate the keratinocyte hyperproliferation and immune cell infiltration visible in plaques while simultaneously exerting systemic effects. These mediators promote oxidative stress that damages red blood cell membranes and shortens erythrocyte survival, widening the RDW. They also suppress albumin synthesis and increase vascular permeability, lowering serum albumin. Recent experimental work has even suggested that abnormal erythrocytes, filtered inefficiently by the spleen, may create a hypoxic microenvironment that favors psoriatic inflammation, providing a direct mechanistic bridge between red cell abnormalities and skin disease. RAR, by integrating both an elevated RDW and a depressed albumin into one metric, may therefore function as a compact readout of the very inflammatory and hypoxic milieu that sustains psoriasis.

The study is not without limitations, and the authors are careful to frame their findings as hypothesis-generating rather than practice-changing. The cross-sectional design means the data show association, not causation: it is equally possible that subclinical inflammation from early psoriasis alters blood indices, or that shared upstream factors drive both. Psoriasis status relied on self-reported clinician diagnosis, which may undercount mild or undiagnosed cases, and the analysis could not capture disease severity, duration, or treatment status. The researchers explicitly call for prospective studies to confirm the findings and to determine whether RAR can predict incident psoriasis, track disease activity over time, or respond to effective therapy. Prior work has shown that biologic treatment can reduce measurable vascular inflammation in psoriasis patients, raising the tantalizing question of whether successful treatment also normalizes RAR.

Still, the appeal of the finding lies in its accessibility. RDW and albumin are measured in virtually every hospital laboratory on the planet, typically for a few dollars, with no specialized equipment or additional blood draw. If prospective research validates RAR as a psoriasis marker, it could offer clinicians a zero-cost screening signal embedded in tests already ordered for other reasons, potentially prompting earlier dermatology referral for patients whose skin symptoms have gone unreported. It could also aid research into the systemic burden of psoriasis, complementing established markers like C-reactive protein and newer indices such as the neutrophil percentage-to-albumin ratio. For now, the message is one of cautious excitement: a humble ratio, computed from two of the oldest measurements in medicine, appears to carry a whisper of information about one of dermatology’s most visible inflammatory diseases, and the scientific community will be watching closely as larger, longitudinal studies put that whisper to the test.

Subject of Research: Association between the red blood cell distribution width-to-albumin ratio and psoriasis prevalence in US adults

Article Title: The association between adult red blood cell width to albumin ratio (RAR) and psoriasis: a retrospective cross-sectional study

Article References: Gao, A., Wei, Z., Ye, X., Shao, W., & Hu, Y. (2026). The association between adult red blood cell width to albumin ratio (RAR) and psoriasis: a retrospective cross-sectional study. Archives of Dermatological Research, 318(1), Article 447. https://doi.org/10.1007/s00403-026-04922-y

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04922-y

Keywords: psoriasis, RAR, red cell distribution width, albumin, biomarker, NHANES, inflammation, cross-sectional study, dermatology, logistic regression, systemic inflammation, epidemiology